Edition:
United Kingdom

Theratechnologies Inc (TH.TO)

TH.TO on Toronto Stock Exchange

7.18CAD
3:30pm BST
Change (% chg)

$0.15 (+2.13%)
Prev Close
$7.03
Open
$7.10
Day's High
$7.20
Day's Low
$7.05
Volume
12,201
Avg. Vol
175,023
52-wk High
$14.75
52-wk Low
$6.72

Latest Key Developments (Source: Significant Developments)

Theratechnologies Announces Financial Results For The First Quarter Of 2019
Thursday, 4 Apr 2019 

April 4 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2019.Q1 NET SALES OF $15.2 MILLION, UP 86%.Q1 LOSS PER SHARE $0.02.QTRLY LOSS PER SHARE $0.02.  Full Article

Theratechnologies Says FDA Approves Novel Single-Vial Formulation Of Egrifta
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Theratechnologies Inc ::FDA APPROVES NOVEL SINGLE-VIAL FORMULATION OF EGRIFTA®.THERATECHNOLOGIES INC - FDA APPROVES EGRIFTA FOR TREATMENT OF EXCESS ABDOMINAL VISCERAL ADIPOSE TISSUE IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY.  Full Article

European Medicines Agency Validates Marketing Authorization Application For Trogarzo
Friday, 14 Sep 2018 

Sept 14 (Reuters) - Theratechnologies Inc ::EUROPEAN MEDICINES AGENCY VALIDATES MARKETING AUTHORIZATION APPLICATION FOR TROGARZO.EMA WILL REVIEW APPLICATION FOR TROGARZO UNDER ACCELERATED ASSESSMENT PROCEDURE.SEEKS TO OBTAIN APPROVAL FOR TROGARZO FOR TREATMENT OF MULTIDRUG RESISTANT HUMAN IMMUNODEFICIENCY VIRUS-1 IN EUROPEAN UNION.RELATED TO EMA CONFIRMING VALIDITY OF MARKETING AUTHORIZATION APPLICATION FOR TROGARZO, START OF PROCEDURE DATE BEEN SET TO SEPT 13.  Full Article

Theratechnologies Files Marketing Authorization Application For Trogarzo
Tuesday, 28 Aug 2018 

Aug 28 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES FILES MARKETING AUTHORIZATION APPLICATION FOR TROGARZO IN EUROPE.THERATECHNOLOGIES INC - EMA HAS UNTIL MID-SEPTEMBER TO CONFIRM WHETHER APPLICATION IS COMPLETE.  Full Article

Theratechnologies Reports Q4 Loss Per Share Of C$0.06
Wednesday, 7 Feb 2018 

Feb 7 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR FISCAL YEAR 2017.Q4 REVENUE C$12.6 MILLION VERSUS C$10.38 MILLION.Q4 LOSS PER SHARE C$0.06.  Full Article

Theratechnologies Q3 loss per share c$0.04
Thursday, 5 Oct 2017 

Oct 5 (Reuters) - Theratechnologies Inc ::Theratechnologies announces financial results for third quarter of 2017.Q3 loss per share c$0.04.Q3 earnings per share view c$-0.03 -- Thomson Reuters I/B/E/S.Theratechnologies - ‍net sales revenue of Egrifta for fiscal 2017 is now expected to be in range of $42 million to $44 million​.  Full Article

Theratechnologies reports Q2 loss per share C$0.13
Wednesday, 12 Jul 2017 

July 12 (Reuters) - Theratechnologies Inc -:Theratechnologies announces financial results for second quarter of 2017.Q2 loss per share c$0.13.Q2 earnings per share view c$-0.03 -- Thomson Reuters I/B/E/S.Theratechnologies Inc - ‍no change in our previously reported guidance for 2017​.Theratechnologies Inc - ‍consolidated revenue for three-month ended May 31, 2017 was $10.016 million compared to $9.027 million.  Full Article

Theratechnologies says FDA sets PDUFA date of Jan 3 for ibalizumab application
Friday, 30 Jun 2017 

June 30 (Reuters) - Theratechnologies Inc ::FDA grants priority review to HIV monoclonal antibody and long-acting investigational antiretroviral ibalizumab.FDA has set a prescription drug user fee act target action date of January 3, 2018, for ibalizumab application.  Full Article